In addition, JAK3 mutations were also reported in CTCL (3%) [6,8,25], T-PLL (30%) [26], ATLL (5%) [6,25], epitheliotropic intestinal T-cell lymphoma (EITL, 35%) [27], EATL [13] and ocular adnexal marginal zone lymphomas (OAML) (11%) [28], resulting in the activation of key cell survival pathways, including JAK3/STAT, with some known gain-of-function mutational hotspots. This evidence concerns the gene JAK3 and adult T-cell leukemia/lymphoma.